Abivax Shares Mark Five Consecutive Sessions of Gains, Surpassing €103
On Wednesday, April 8, the stock of the French biotech company Abivax significantly advanced in a buoyant Parisian market. Abivax traded around €103.10 after closing at €99.55 the previous day, marking its fifth consecutive session of gains and bringing its weekly performance to over 10%.
Technical Breakthrough and Short-Term Dynamics
During the session, Abivax surpassed its 50-day moving average of €101.00, a threshold it had not consistently exceeded for several weeks. This technical breakthrough occurs as the stock now moves in the upper part of its Bollinger Bands, at 63% of the range between the lower bound (€87.69) and the upper bound (€112.17), without approaching the overbought zone. The RSI, at 49, remains in neutral territory, suggesting that the recent upward movement does not yet show signs of excess. Over three months, the performance remains negative with a decline of nearly 6%. However, the short-term dynamics contrast with this trend: the increase of more than 10% in a week brings the price back to the resistance identified at €110.20. A sustained crossing of this level would be an additional signal for technical traders. The major support is located at €88.80.
Market Context and Comparative Performance
Today's rise occurs amidst a strong rebound in the CAC 40, which is up nearly 4% during the session at 8222 points. The SBF 120 is advancing in comparable proportions (+3.92%). Abivax, with a beta of 1.68, typically amplifies market movements, partly explaining the extent of its progress this morning. The monthly volatility of the stock remains high, at 56.27%, a characteristic level for small-cap biotech sector companies. In terms of sector comparables, Sanofi is up 0.37% and UCB has advanced 0.95% during the session, significantly more moderate variations. The next important date for Abivax shareholders is set for June 1, 2026, when the company will publish its first-quarter results. This milestone will be crucial to assess the progress of the company's clinical programs and its cash consumption trajectory, two parameters closely monitored by the market.
